Literature DB >> 7763975

Engineering bispecific antibodies.

P Holliger1, G Winter.   

Abstract

Bispecific antibodies have immense potential as reagents and in medicine. Until recently, they were made by combining monoclonal antibodies of two different specificities in vitro, or by fusion of the corresponding hybridomas. Protein engineering now offers the chance to construct a range of small 'designer' bispecific antibodies using antibody fragments as building blocks.

Mesh:

Substances:

Year:  1993        PMID: 7763975     DOI: 10.1016/0958-1669(93)90010-t

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  13 in total

Review 1.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

Review 2.  Targeting of peripheral blood T lymphocytes.

Authors:  R L Bolhuis; H R Hoogenboom; J W Gratama
Journal:  Springer Semin Immunopathol       Date:  1996

3.  Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59.

Authors:  J Yu; T Caragine; S Chen; B P Morgan; A B Frey; S Tomlinson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

4.  Glycoengineering of antibody (Herceptin) through yeast expression and in vitro enzymatic glycosylation.

Authors:  Chiu-Ping Liu; Tsung-I Tsai; Ting Cheng; Vidya S Shivatare; Chung-Yi Wu; Chung-Yi Wu; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

Review 5.  Engineering recombinant antibodies for immunotherapy.

Authors:  D Neri; H Petrul; G Roncucci
Journal:  Cell Biophys       Date:  1995-08

Review 6.  Therapeutic antibodies for autoimmunity and inflammation.

Authors:  Andrew C Chan; Paul J Carter
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

7.  Expression of recombinant multi-coloured fluorescent antibodies in gor -/trxB- E. coli cytoplasm.

Authors:  Anatoliy Markiv; Richard Beatson; Joy Burchell; Ravi V Durvasula; Angray S Kang
Journal:  BMC Biotechnol       Date:  2011-11-30       Impact factor: 2.563

8.  Efficient production of human bivalent and trivalent anti-MUC1 Fab-scFv antibodies in Pichia pastoris.

Authors:  Steve Schoonooghe; Vladimir Kaigorodov; Monika Zawisza; Caroline Dumolyn; Jurgen Haustraete; Johan Grooten; Nico Mertens
Journal:  BMC Biotechnol       Date:  2009-08-11       Impact factor: 2.563

9.  Recombinant norovirus-specific scFv inhibit virus-like particle binding to cellular ligands.

Authors:  Khalil Ettayebi; Michele E Hardy
Journal:  Virol J       Date:  2008-01-31       Impact factor: 4.099

10.  Creation of a gated antibody as a conditionally functional synthetic protein.

Authors:  Smita B Gunnoo; Helene M Finney; Terry S Baker; Alastair D Lawson; Daniel C Anthony; Benjamin G Davis
Journal:  Nat Commun       Date:  2014-07-30       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.